Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

EMA will assess potential COVID-19 vaccine on ‘case by case’ basis

Agency will not specify a minimum level of efficacy, according to Reuters

- PMLiVE

FDA briefing documents back Biogen’s Alzheimer’s drug aducanumab

Documents show the efficacy data for the drug as being ‘exceptionally persuasive’

- PMLiVE

AZ is expecting late-stage COVID-19 vaccine data this year

Company reiterated timeline in third quarter results

- PMLiVE

The new world of association congresses

It’s time we reimagined the rules of engagement

- PMLiVE

Sanofi set to acquire Kiadis for €308m

Acquisition will see French pharma gain access to NK-cell platform

- PMLiVE

Pfizer, Mylan move ahead with generics merger and spin-out

The merger had faced a set-back as a result of COVID-19 disruption

- PMLiVE

NHS gearing up for possible pre-Christmas COVID-19 vaccinations

NHS chief exec said the NHS is getting ready to administer vaccines

Lucid Group expand its UK office footprint in Macclesfield

Lucid Group is increasing its share of office space on the popular Tytherington Business Village, after a sustained period of growth, which has seen it outperform a buoyant marketplace and taken...

Lucid Group Communications Limited

- PMLiVE

NICE – but not enough

Why evidence is better than assumption when executing commercial strategy

AstraZeneca AZ

AZ confirms the UK’s MHRA has started rolling review of its COVID-19 vaccine

Regulatory agency will review data as and when it becomes available

- PMLiVE

CureVac reveals early data for mRNA-based COVID-19 vaccine candidate

German biotech says vaccine demonstrated an immune response in phase 1/2

- PMLiVE

Regeneron halts enrolment of severely ill patients in COVID-19 antibody trial

Trial modified based on recommendations from independent data monitoring committee

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links